Category: St. Jude MedicalSyndicate content

Medicare proposes TAVI reimbursement guidelines

February 6, 2012 by MassDevice staff

The Centers for Medicare & Medicaid Services release a proposal for reimbursement of transcatheter aortic valve implantation procedures, a boon for Edwards Lifesciences' Sapien and its position as the only replacement valve system with FDA clearance for the U.S. market.

Updated 12:10 p.m. with comments from Edwards Lifesciences.

TAVI devices

Clockwise from top left: Medtronic's CoreValve, Edwards Lifesciences' Sapien, St. Jude Medical's Portico

The Centers for Medicare & Medicaid Services released a proposal detailing guidelines for reimbursement of transcatheter aortic valve implantation procedures for treating severe symptomatic aortic stenosis.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific to hit the acquisitions trail | Wall Street Beat

February 6, 2012 by MassDevice staff

Boston Scientific plans to use the bulk of the $1 billion of the free cash flow it expects to generate this year on acquisitions, according to CFO Jeff Capello; also, Intuitive Surgical, Zoll hit 52-week highs; and analysts' ups and downs.

MassDevice.com Wall Street Beat

Boston Scientific (NYSE:BSX) plans to hoard most of the more than $1 billion in free cash flow it expects to generate this year so it can make acquisitions to boost its top line, CFO Jeff Capello told analysts last week.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AngioDynamics CEO: Navilyst deal hits the reset button | Wall Street Beat

February 1, 2012 by MassDevice staff

AngioDynamics CEO Joseph DeVivo tells MassDevice that the $372 million deal to acquire Navilyst Medical is a chance to set the combined companies on a sound foundation; plus, CEO pay: $1.4M for no growth?; Greenway Medical readies IPO; Exactech releases Q4 prelims, 2012 guidance; and analysts' ups and downs.

Updated February 1, 2012 at 5:30 p.m.

MassDevice.com Wall Street Beat

The $372 million buyout of Navilyst Medical by AngioDynamics (NSDQ:ANGO) is a reset button that will reinforce the combined operation for the future, AngioDynamics CEO Joe DeVivo told MassDevice this afternoon.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +7 | The top 7 med-tech stories for the week of January 23, 2012

January 28, 2012 by MassDevice staff

J&J's DePuy to stop selling all custom devices; FDA announces 2012 medical device priorities; cardiologists charged with Medicare fraud in over-stenting cases; Sanovas expands ahead of commercial launch; St. Jude responds to Riata summit; and a judge rules Cordis patents invalid.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

Venture capital outlook a mixed bag | Wall Street Beat

January 27, 2012 by MassDevice staff

The outlook for venture capital this year has its bright and dark spots, according to National Venture Capital Assn. president Mark Heesen; also, PE climate "schizo"; Leerink Swann sees upside in health care market; a bullish take on St. Jude Medical; and analysts' ups and downs.

MassDevice.com Wall Street Beat

The volatility of the stock markets last year was mirrored in the venture capital arena, according to Mark Heesen, president of the National Venture Capital Assn.

"Be prepared for a roller coaster ride here, because that’s where we’ve been for the past year – and that’s where we’re going," Heesen told Xconomy.

Thoratec settles Oracle beef | Wall Street Beat

January 26, 2012 by MassDevice staff

Thoratec Corp. says it's settled a beef with activist investor group Oracle Investment Management over whether to sell the company; also, NuVasive jumps on legal ruling; Oridion releases Q4, 2011 prelims; AngioDynamics announces recall, updates guidance; cosmetic device market on the mend?; and analysts' ups and downs.

MassDevice.com Wall Street Beat

Thoratec Corp. (NSDQ:THOR) said it reached an agreement with one of its major institutional shareholders, Oracle Investment Management, over whether or not the heart pump maker should hire an investment bank to find a buyer.

Greenwich, Conn.-based Oracle, which holds a 5.2% stake in the heart pump maker, recommended that Thoratec retain an investment bank to explore strategic alternatives, including sale to a larger company.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

St. Jude Medical beats The Street, gets a little love

January 25, 2012 by MassDevice staff

St. Jude gained a few points on Wall Street by beating analysts' profit expectations for 2011 by a penny.

St. Jude Medical logo

St. Jude Medical (NYSE:STJ) got a little love from Wall Street after posting 2011 earnings results that beat analysts' forecasts by 1 cent.

The St. Paul, Minn.-based medical device maker posted $5.61 billion in sales for 2011, an 8.7% bump over $5.17 billion in 2010.

Non-adjusted earnings slid to $864 million, or $2.64 earned per diluted share, representing a 4.7% decrease from the $907 million, or $2.75 per diluted share, earned in 2010.